Journal
PHARMACEUTICALS
Volume 14, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ph14010015
Keywords
COVID-19; dimethyl fumarate; Nrf2; therapeutics
Categories
Ask authors/readers for more resources
COVID-19 is spreading rapidly worldwide, creating a need for urgent therapeutic options; proposing the use of dimethyl fumarate to address immune dysregulation, hyperinflammation, and oxidative stress; the drug, already approved for other diseases, has the potential to treat severe cases of COVID-19.
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available